TABLE 5.
Differences in the Occurrence of COPD Exacerbations 6 Months Pre- and Postconversion from Fluticasone/Salmeterol to Mometasone/Formoterol by Subgroup
| Patients with ࣙ 1 Exacerbation | |||
|---|---|---|---|
| Subgroups | Fluticasone/Salmeterol % (n) | Mometasone/Formoterol % (n) | P Valuea |
| Female (n = 307) | 35.8 (110) | 32.6 (100) | 0.378 |
| Male (n = 214) | 31.8 (68) | 22.9 (49) | 0.023b |
| Asthma (n = 251) | 39.4 (99) | 31.1 (78) | 0.026b |
| CHF (n = 52) | 38.5 (20) | 30.8 (16) | 0.480 |
| Lung cancer (n = 18) | 27.8 (5) | 16.7 (3) | 0.683 |
| Conversion to P&T Committee-recommended dose of mometasone/formoterolc (n = 439) | 31.4 (138) | 28.5 (125) | 0.309 |
| Conversion to lower than P&T Committee-recommended dose of mometasone/formoterolc (n = 29) | 41.4 (12) | 27.6 (8) | 0.289 |
| Conversion to higher than P&T Committee-recommended dose of mometasone/formoterolc (n = 53) | 52.8 (28) | 30.2 (16) | 0.014b |
a P values calculated with McNemar’s test.
b Statistically significant difference.
c Fluticasone/salmeterol 250/50 mcg, 1 puff by mouth twice daily, recommended to be converted to mometasone/formoterol 100/5 mcg, 2 puffs by mouth twice daily; fluticasone/salmeterol 500/50 mcg, 1 puff by mouth twice daily, recommended to be converted to mometasone/formoterol 200/5 mcg, 2 puffs by mouth twice daily.
CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; P…T = Pharmacy and Therapeutics.